Adobe sees a dip in its shares following a lawsuit by the FTC, which accuses the company of not fully disclosing termination fees, thus trapping consumers in costly year-long subscriptions.
In a significant legal move, Tesla Inc. is reportedly suing Matthews International, claiming the company misappropriated Tesla's proprietary dry electrode battery technology to the detriment of Tesla's competitive edge and innovation.
Xponential Fitness announces Mark King as the new CEO effective June 17, 2024, boosting investor confidence. King, with a robust track record at Taco Bell and Adidas, aims to enhance global brand performance and franchise operations.
Shares of Polestar Automotive Holding are surging today after the company said it is expanding its global presence and enhancing its retail strategy to include both existing and new markets as its electric vehicle (EV) lineup grows.
U.S. Steel forecasts Q2 2024 adjusted net earnings per share of $0.76 to $0.80, under the consensus estimate of $0.83, amidst stable domestic demand but challenging market dynamics, as detailed by CEO David B. Burritt.
OpenAI and startup Color Health have developed an AI assistant, named 'copilot', to support physicians in creating personalized cancer care plans, emphasizing the tool's role in augmenting rather than replacing human expertise.
Aaron's Company shares soared as it announced an acquisition by fintech firm IQVentures for $10.10 per share, a 34% premium over its recent closing price, marking a significant shift to private ownership with a valuation around $504 million.
Cisco reveals plans for a new cybersecurity hub in Taiwan to tackle increasing cyberattacks suspected from mainland China, reflecting its commitment to strengthening digital security and addressing the global talent shortage in cybersecurity.
AstraZeneca's breakthrough drug, Imfinzi, combined with chemotherapy, has been officially approved by the FDA to treat advanced forms of endometrial cancer with mismatch repair deficiency. This critical approval is based on Phase III trial results showing a 58% reduction in disease progression, promising improved outcomes for those battling this severe cancer.
Adidas AG is reportedly probing deep into accusations of bribery within its China operations, following whistleblower allegations of high-ranking officials embezzling millions. Despite the severity, no staff have been suspended as Adidas reassures its commitment to high ethical standards.